ABVC BioPharma, Inc.
ABVC
$0.96
-$0.10-9.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -100.00% | 20.91% | 36.53% |
| Total Other Revenue | -- | -- | -- | 91.77% | 98.29% |
| Total Revenue | -100.00% | -100.00% | -100.00% | 56.53% | 186.88% |
| Cost of Revenue | -- | -- | -- | -100.00% | -99.82% |
| Gross Profit | -100.00% | -100.00% | -100.00% | 115.73% | 1,292.07% |
| SG&A Expenses | 50.46% | 169.91% | 39.63% | 18.70% | -29.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -110.84% | -110.84% | -110.84% | 633.90% | 447.92% |
| Total Operating Expenses | 46.65% | 157.13% | 35.65% | 13.41% | -31.83% |
| Operating Income | -60.83% | -207.16% | -50.18% | -8.54% | 36.51% |
| Income Before Tax | -67.51% | -168.70% | -55.56% | -4.68% | 43.15% |
| Income Tax Expenses | -97.92% | 121.81% | 121.81% | -62.81% | -62.15% |
| Earnings from Continuing Operations | -66.64% | -178.51% | -59.29% | -3.84% | 43.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 47.11% | 35.93% | 31.46% | -53.33% | -40.73% |
| Net Income | -68.18% | -196.37% | -61.30% | -11.47% | 43.49% |
| EBIT | -60.83% | -207.16% | -50.18% | -8.54% | 36.51% |
| EBITDA | -61.48% | -210.73% | -50.67% | -8.58% | 36.70% |
| EPS Basic | -5.12% | -71.50% | 16.84% | 36.33% | 78.13% |
| Normalized Basic EPS | 5.80% | -60.32% | 26.72% | 21.73% | 78.08% |
| EPS Diluted | -5.03% | -70.50% | 16.75% | 35.86% | 77.94% |
| Normalized Diluted EPS | 5.80% | -60.32% | 26.72% | 21.73% | 78.08% |
| Average Basic Shares Outstanding | 71.65% | 75.01% | 72.17% | 71.44% | 82.34% |
| Average Diluted Shares Outstanding | 71.65% | 75.01% | 72.17% | 71.44% | 82.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |